Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. HIMS
HIMS logo

HIMS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
27.240
Open
26.840
VWAP
24.95
Vol
68.30M
Mkt Cap
5.43B
Low
23.760
Amount
1.70B
EV/EBITDA(TTM)
35.71
Total Shares
227.94M
EV
6.29B
EV/OCF(TTM)
20.98
P/S(TTM)
2.81
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
Show More

Events Timeline

(ET)
2026-03-12
09:00:00
Global Market Volatility and Rising Oil Prices Impact Stock Futures
select
2026-03-11 (ET)
2026-03-11
12:10:00
Hims & Hers Stock Rises 14.5% to $26.87
select
2026-03-11
11:40:00
Hims and Hers Health Shares Rise 11.29%
select
2026-03-10 (ET)
2026-03-10
20:30:00
Hims & Hers Health Appoints Kathryn Beiser as Chief Communications Officer
select
2026-03-10
10:10:00
Hims & Hers Stock Rises 12% to $24.83
select

News

stocktwits
8.5
03-11stocktwits
PinnedHims Stock Soars 50% Following Novo Partnership and Legal Settlement
  • Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
  • Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
  • Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
  • Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
Fool
2.0
03-12Fool
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
  • Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
  • Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
  • Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
  • Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
CNBC
2.0
03-12CNBC
Midday Stock Highlights: Notable Movements in Multiple Stocks
  • Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
  • Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
  • Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
  • Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
Fool
7.5
03-12Fool
Novo Nordisk Partners with Hims & Hers to Boost Sales
  • Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
  • Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
  • Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
  • Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
Benzinga
7.5
03-12Benzinga
Hims & Hers Partners with Novo Nordisk, Boosting Stock Sentiment
  • Partnership Formation: Hims & Hers has established a new partnership with Novo Nordisk to introduce branded GLP-1 treatments like Ozempic and Wegovy, which alleviates legal concerns and strengthens collaboration with a major pharmaceutical company, likely boosting market confidence.
  • Weight Loss Strategy Shift: The company is transitioning its U.S. weight-loss business towards FDA-approved treatments, ceasing active promotion of compounded GLP-1 drugs, allowing existing patients to switch to branded therapies when clinically appropriate, aiming to enhance treatment efficacy and patient satisfaction.
  • Short Interest Pressure: Short interest in Hims has risen from 81.01 million to 84.96 million shares, with 46.09% of the public float currently held short; given the average daily volume of 32.93 million shares, it would take 2.58 days for short sellers to cover their positions, indicating market attention on potential price rebounds.
  • Technical Analysis Status: Hims is trading 59.9% above its 20-day simple moving average but 16% below its 100-day moving average, indicating a strong short-term bounce that has yet to repair the longer-term trend, with shares down 23.73% over the past 12 months.
moomoo
2.0
03-12moomoo
HIMS & HERS HEALTH STOCK RISES 1% AFTER NEARLY 65% INCREASE OVER LAST THREE SESSIONS
  • Health Share Increase: HIMS & HERS reported a 1% increase in health shares following a significant surge in past sessions.

  • Surge in Sessions: The company experienced nearly a 65% surge in sessions over the last three sessions.

Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
Wall Street analysts forecast HIMS stock price to rise
3 Buy
6 Hold
3 Sell
Hold
Current: 0.000
sliders
Low
16.50
Averages
32.95
High
60.00
Current: 0.000
sliders
Low
16.50
Averages
32.95
High
60.00
Barclays
Glen Santangelo
Overweight
maintain
$25 -> $29
AI Analysis
2026-03-11
New
Reason
Barclays
Glen Santangelo
Price Target
$25 -> $29
AI Analysis
2026-03-11
New
maintain
Overweight
Reason
Barclays analyst Glen Santangelo raised the firm's price target on Hims & Hers to $29 from $25 and keeps an Overweight rating on the shares. The rally post the Novo Nordisk agreement highlights the incremental market opportunity and removal of the legal overhang for Hims & Hers shares, the analyst tells investors in a research note. Barclays believes the market is still underappreciating Hims' opportunity from new products.
Deutsche Bank
Hold
maintain
$25 -> $28
2026-03-10
New
Reason
Deutsche Bank
Price Target
$25 -> $28
2026-03-10
New
maintain
Hold
Reason
Deutsche Bank raised the firm's price target on Hims & Hers to $28 from $25 and keeps a Hold rating on the shares. The company announced a new partnership with Novo Nordisk and a strategic shift in its GLP-1 offerings away from compounded semaglutide, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HIMS
Unlock Now

Valuation Metrics

The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 56.69, compared to its 5-year average forward P/E of 2.96. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.96
Current PE
56.69
Overvalued PE
57.87
Undervalued PE
-51.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.17
Current EV/EBITDA
23.70
Overvalued EV/EBITDA
44.96
Undervalued EV/EBITDA
-28.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.28
Current PS
2.87
Overvalued PS
5.40
Undervalued PS
1.16

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Most bullish stocks over 10
Intellectia · 280 candidates
Price: >= $10.00Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Macd: bullish
Ticker
Name
Market Cap$
top bottom
HIMS logo
HIMS
Hims & Hers Health Inc
5.90B
HIMX logo
HIMX
Himax Technologies Inc
1.60B
AXTI logo
AXTI
AXT Inc
2.62B
TENX logo
TENX
Tenax Therapeutics Inc
251.43M
XENE logo
XENE
Xenon Pharmaceuticals Inc
4.91B
BODI logo
BODI
Beachbody Company Inc
78.33M
stocks that spiked above $3 today
Intellectia · 25 candidates
Price: >= $10.00Volume: >= 1,000,000Price Change Pct: >= $8.00
Ticker
Name
Market Cap$
top bottom
NVTS logo
NVTS
Navitas Semiconductor Corp
2.50B
PZZA logo
PZZA
Papa John's International Inc
1.28B
NBIS logo
NBIS
Nebius Group NV
28.34B
SOC logo
SOC
Sable Offshore Corp
2.44B
PRCT logo
PRCT
Procept Biorobotics Corp
1.57B
PTRN logo
PTRN
Pattern Group Inc
2.20B
what should I say trade today stocks wise
Intellectia · 79 candidates
Price: $5.00 - $150.00Volume: >= 1,000,000Price Change Pct: $2.00 - $15.00Beta: HighRiskList Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PATH logo
PATH
UiPath Inc
6.20B
HIMS logo
HIMS
Hims & Hers Health Inc
5.35B
INTC logo
INTC
Intel Corp
233.62B
OPEN logo
OPEN
Opendoor Technologies Inc
4.80B
IREN logo
IREN
IREN Ltd
12.67B
WULF logo
WULF
Terawulf Inc
6.09B
one day increase of at least 2 percent
Intellectia · 453 candidates
Region: USPrice Change Pct: >= $2.00
Ticker
Name
Market Cap$
top bottom
ASNS logo
ASNS
Actelis Networks Inc
3.29M
ACXP logo
ACXP
Acurx Pharmaceuticals Inc
7.39M
GSUN logo
GSUN
Golden Sun Technology Group Ltd
5.08M
CVGI logo
CVGI
Commercial Vehicle Group Inc
59.50M
KALA logo
KALA
KALA BIO Inc
267.84M
SOS logo
SOS
Sos Ltd
12.07M
What stocks are trending for daytrading?
Intellectia · 310 candidates
Region: USPrice: $0.50 - $80.00Relative Vol: >= 1.30Beta: ModerateRisk, HighRiskIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
NIO logo
NIO
NIO Inc
14.15B
AAL logo
AAL
American Airlines Group Inc
7.34B
HIMS logo
HIMS
Hims & Hers Health Inc
5.35B
RIVN logo
RIVN
Rivian Automotive Inc
20.53B
PATH logo
PATH
UiPath Inc
6.20B
WIT logo
WIT
Wipro Ltd
26.72B
5 stocks under $20 to t22rade everyday
Intellectia · 1186 candidates
Price: $1.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEWeekly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
KVUE logo
KVUE
Kenvue Inc
35.52B
HIMS logo
HIMS
Hims & Hers Health Inc
3.80B
SOFI logo
SOFI
SoFi Technologies Inc
26.11B
F logo
F
Ford Motor Co
55.19B
U logo
U
Unity Software Inc
9.27B
WULF logo
WULF
Terawulf Inc
6.71B
biggest loser in stock market this week
Intellectia · 18 candidates
Market Cap: >= 300.00MList Exchange: XNYS, XNAS, XASEWeek Price Change Pct: <= $-20.00Monthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
KD logo
KD
Kyndryl Holdings Inc
2.54B
FLNC logo
FLNC
Fluence Energy Inc
3.49B
MOH logo
MOH
Molina Healthcare Inc
6.40B
HIMS logo
HIMS
Hims & Hers Health Inc
3.92B
MNDY logo
MNDY
monday.com Ltd
3.82B
PI logo
PI
Impinj Inc
3.34B
RSI below 30
Intellectia · 33 candidates
Market Cap: >= 1000.00MBeta: HighRiskWeekly Average Turnover: >= 1,000,000Rsi 14: <= 30Month Price Change Pct: <= $-10.00
Ticker
Name
Market Cap$
top bottom
CRM logo
CRM
Salesforce Inc
207.62B
SHOP logo
SHOP
Shopify Inc
180.36B
INTU logo
INTU
Intuit Inc
146.07B
NOW logo
NOW
ServiceNow Inc
130.11B
NET logo
NET
Cloudflare Inc
59.54B
ADSK logo
ADSK
Autodesk Inc
54.58B
stocks that went down now
Intellectia · 25 candidates
Beta: HighRiskWeekly Average Turnover: >= 10,000,000Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-12.00Quarter Price Change Pct: <= $-20.00
Ticker
Name
Market Cap$
top bottom
ORCL logo
ORCL
Oracle Corp
499.58B
INTU logo
INTU
Intuit Inc
146.07B
CEG logo
CEG
Constellation Energy Corp
106.67B
HOOD logo
HOOD
Robinhood Markets Inc
95.24B
NET logo
NET
Cloudflare Inc
59.54B
TEAM logo
TEAM
Atlassian Corp
32.21B
stocks with lowest KDJ values
Intellectia · 33 candidates
Market Cap: >= 1000.00MBeta: HighRiskWeekly Average Turnover: >= 1,000,000Rsi 14: <= 30Month Price Change Pct: <= $-10.00
Ticker
Name
Market Cap$
top bottom
CRM logo
CRM
Salesforce Inc
207.62B
SHOP logo
SHOP
Shopify Inc
180.36B
INTU logo
INTU
Intuit Inc
146.07B
NOW logo
NOW
ServiceNow Inc
130.11B
NET logo
NET
Cloudflare Inc
59.54B
ADSK logo
ADSK
Autodesk Inc
54.58B

Whales Holding HIMS

H
Himension Capital (Singapore) Pte Ltd
Holding
HIMS
+5.24%
3M Return
D
Divisadero Street Capital Management, LP
Holding
HIMS
-2.50%
3M Return
C
Clear Street LLC
Holding
HIMS
-3.07%
3M Return
T
The State of Michigan Retirement Systems
Holding
HIMS
-3.27%
3M Return
C
Cantor Fitzgerald Asset Management
Holding
HIMS
-3.59%
3M Return
S
Summit Trail Advisors, LLC
Holding
HIMS
-3.88%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Hims & Hers Health Inc (HIMS) stock price today?

The current price of HIMS is 23.84 USD — it has decreased -7.88

What is Hims & Hers Health Inc (HIMS)'s business?

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

What is the price predicton of HIMS Stock?

Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is32.95 USD with a low forecast of 16.50 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Hims & Hers Health Inc (HIMS)'s revenue for the last quarter?

Hims & Hers Health Inc revenue for the last quarter amounts to 617.82M USD, increased 28.41

What is Hims & Hers Health Inc (HIMS)'s earnings per share (EPS) for the last quarter?

Hims & Hers Health Inc. EPS for the last quarter amounts to 0.08 USD, decreased -27.27

How many employees does Hims & Hers Health Inc (HIMS). have?

Hims & Hers Health Inc (HIMS) has 2442 emplpoyees as of March 13 2026.

What is Hims & Hers Health Inc (HIMS) market cap?

Today HIMS has the market capitalization of 5.43B USD.